Elicio Therapeutics Inc./$ELTX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Elicio Therapeutics Inc.
Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking.
Ticker
$ELTX
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
32
ISIN
US28657F1030
Website
ELTX Metrics
BasicAdvanced
$116M
-
-$3.98
-
-
Price and volume
Market cap
$116M
52-week high
$8.84
52-week low
$4.60
Average daily volume
37K
Financial strength
Current ratio
1.834
Quick ratio
1.608
Long term debt to equity
54.638
Total debt to equity
65.038
Interest coverage (TTM)
-76.44%
Management effectiveness
Return on assets (TTM)
-108.03%
Return on equity (TTM)
-744.59%
Valuation
Price to book
12.97
Price to tangible book (TTM)
12.97
Price to free cash flow (TTM)
-2.648
Growth
Earnings per share change (TTM)
-22.93%
3-year earnings per share growth (CAGR)
33.42%
ELTX News
AllArticlesVideos
Elicio Therapeutics Reports Inducement Grant to New Chief Strategy and Financial Officer and Other New Hires
GlobeNewsWire·1 month ago
Elicio Therapeutics Reports 2024 Financial Results and Provides Corporate Updates
GlobeNewsWire·2 months ago
Elicio Therapeutics Appoints Preetam Shah, Ph.D., MBA, as Chief Strategy and Financial Officer
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Elicio Therapeutics Inc. stock?
Elicio Therapeutics Inc. (ELTX) has a market cap of $116M as of May 31, 2025.
What is the P/E ratio for Elicio Therapeutics Inc. stock?
The price to earnings (P/E) ratio for Elicio Therapeutics Inc. (ELTX) stock is 0 as of May 31, 2025.
Does Elicio Therapeutics Inc. stock pay dividends?
No, Elicio Therapeutics Inc. (ELTX) stock does not pay dividends to its shareholders as of May 31, 2025.
When is the next Elicio Therapeutics Inc. dividend payment date?
Elicio Therapeutics Inc. (ELTX) stock does not pay dividends to its shareholders.
What is the beta indicator for Elicio Therapeutics Inc.?
Elicio Therapeutics Inc. (ELTX) does not currently have a Beta indicator.